235 results on '"Zheng, Yi-Min"'
Search Results
2. Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants
3. Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy
4. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants
5. WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas
6. Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion
7. KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma
8. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
9. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion
10. Neutralizing antibody response to SARS‐CoV‐2 bivalent mRNA vaccine in SIV‐infected rhesus macaques: Enhanced immunity to XBB subvariants by two‐dose vaccination
11. Elevated nuclear localization of glycolytic enzyme TPI1 promotes lung adenocarcinoma and enhances chemoresistance
12. Research on the Application of Blockchain in SMEs Credit Risk
13. TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins
14. Fractional-Order PID Controller Design for Time-Delay Systems Based on Modified Bode’s Ideal Transfer Function
15. circHMGCS1–016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma
16. Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
17. Cancer-derived exosomal circTMEM56 sensitize HCC radiotherapy by augment cGAS-STING pathway in dendritic cells
18. Immune Evasion and Membrane Fusion of SARS-CoV-2 XBB Subvariants EG.5.1 and XBB.2.3
19. Continued evasion of neutralizing antibody response by Omicron XBB.1.16
20. IFITM Proteins Restrict Viral Membrane Hemifusion
21. Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.
22. Neutralization Escape of Omicron XBB, BR.2, and BA.2.3.20 Subvariants
23. Enhanced Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
24. Corrigendum to: “PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma” [J Hepatol 77 (2022) 163-176]
25. Mitochondrial DNA Quantification Correlates with the Developmental Potential of Human Euploid Blastocysts but not with that of Mosaic Blastocysts
26. Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants
27. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
28. Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant
29. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
30. Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants
31. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
32. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
33. TIM-family proteins inhibit HIV-1 release
34. Mitochondrial DNA quantification correlates with the developmental potential of human euploid blastocysts but not with that of mosaic blastocysts.
35. Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants
36. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma
37. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
38. Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
39. Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
40. Fractional-Order PID Controller Design for Time-Delay Systems Based on Modified Bode’s Ideal Transfer Function
41. Additional file 1 of KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma
42. Additional file 2 of KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma
43. SARS-CoV-2 spreads through cell-to-cell transmission
44. Erratum for Zeng et al., “Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H”
45. Neutralization and Stability of SARS-CoV-2 Omicron Variant
46. Double Loop DR-PID Control of A Rotary Inverted Pendulum
47. Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H
48. SERINC proteins potentiate antiviral type I IFN production and proinflammatory signaling pathways
49. Additional file 2 of circHMGCS1–016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma
50. Additional file 3 of circHMGCS1–016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.